EA031003B1 - Способы и фармацевтические композиции для лечения вызванных вирусом гепатита в инфекций - Google Patents

Способы и фармацевтические композиции для лечения вызванных вирусом гепатита в инфекций Download PDF

Info

Publication number
EA031003B1
EA031003B1 EA201690556A EA201690556A EA031003B1 EA 031003 B1 EA031003 B1 EA 031003B1 EA 201690556 A EA201690556 A EA 201690556A EA 201690556 A EA201690556 A EA 201690556A EA 031003 B1 EA031003 B1 EA 031003B1
Authority
EA
Eurasian Patent Office
Prior art keywords
benzimidazol
phenyl
acetamide
chloro
benzofuran
Prior art date
Application number
EA201690556A
Other languages
English (en)
Russian (ru)
Other versions
EA201690556A1 (ru
Inventor
Патрис Андре
Венсан Лотто
Полин Радро
Марин Жилардон
Амори Патен
Дидье Роше
Даниель Краво
Софи Аллаку-Бозек
Original Assignee
Инсерм (Энститю Насьональ Де Ля Сантэ Э Де Ля Решерш Медикаль)
Юниверсите Клод Бернар - Лион 1
Энс - Эколь Нормаль Сюперьёр Де Лион
Сантр Насьональ Де Ля Решерш Сьентифик (Снрс)
Эделрис
Поксел
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Инсерм (Энститю Насьональ Де Ля Сантэ Э Де Ля Решерш Медикаль), Юниверсите Клод Бернар - Лион 1, Энс - Эколь Нормаль Сюперьёр Де Лион, Сантр Насьональ Де Ля Решерш Сьентифик (Снрс), Эделрис, Поксел filed Critical Инсерм (Энститю Насьональ Де Ля Сантэ Э Де Ля Решерш Медикаль)
Publication of EA201690556A1 publication Critical patent/EA201690556A1/ru
Publication of EA031003B1 publication Critical patent/EA031003B1/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • A61K31/522Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • A61K38/212IFN-alpha
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EA201690556A 2013-09-11 2014-09-10 Способы и фармацевтические композиции для лечения вызванных вирусом гепатита в инфекций EA031003B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13306245 2013-09-11
PCT/EP2014/069312 WO2015036442A1 (en) 2013-09-11 2014-09-10 Methods and pharmaceutical compositions for the treatment of hepatitis b virus infection

Publications (2)

Publication Number Publication Date
EA201690556A1 EA201690556A1 (ru) 2016-07-29
EA031003B1 true EA031003B1 (ru) 2018-10-31

Family

ID=49231404

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201690556A EA031003B1 (ru) 2013-09-11 2014-09-10 Способы и фармацевтические композиции для лечения вызванных вирусом гепатита в инфекций

Country Status (25)

Country Link
US (2) US9895380B2 (enrdf_load_stackoverflow)
EP (2) EP3043865B1 (enrdf_load_stackoverflow)
JP (2) JP6366721B2 (enrdf_load_stackoverflow)
KR (1) KR101949251B1 (enrdf_load_stackoverflow)
CN (2) CN110404073B (enrdf_load_stackoverflow)
AU (2) AU2014320463B2 (enrdf_load_stackoverflow)
BR (1) BR112016005507B1 (enrdf_load_stackoverflow)
CA (1) CA2923090C (enrdf_load_stackoverflow)
CY (1) CY1123962T1 (enrdf_load_stackoverflow)
DK (1) DK3043865T3 (enrdf_load_stackoverflow)
EA (1) EA031003B1 (enrdf_load_stackoverflow)
ES (1) ES2846183T3 (enrdf_load_stackoverflow)
HR (1) HRP20201953T1 (enrdf_load_stackoverflow)
HU (1) HUE052856T2 (enrdf_load_stackoverflow)
IL (1) IL244431B (enrdf_load_stackoverflow)
LT (1) LT3043865T (enrdf_load_stackoverflow)
MX (1) MX377523B (enrdf_load_stackoverflow)
MY (1) MY186752A (enrdf_load_stackoverflow)
PH (1) PH12016500431B1 (enrdf_load_stackoverflow)
PL (1) PL3043865T3 (enrdf_load_stackoverflow)
PT (1) PT3043865T (enrdf_load_stackoverflow)
RS (1) RS61540B1 (enrdf_load_stackoverflow)
SI (1) SI3043865T1 (enrdf_load_stackoverflow)
SM (1) SMT202000669T1 (enrdf_load_stackoverflow)
WO (1) WO2015036442A1 (enrdf_load_stackoverflow)

Families Citing this family (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5969471B2 (ja) 2010-07-22 2016-08-17 ギリード・サイエンシズ・インコーポレーテッド パラミクソウイルス科ウイルス感染症を治療するための方法及び化合物
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
US11701369B2 (en) * 2014-09-28 2023-07-18 Huahui Health Ltd. Polymeric bile acid derivatives inhibit Hepatitis B and D virus and NTCP transport
TWI767201B (zh) 2014-10-29 2022-06-11 美商基利科學股份有限公司 絲狀病毒科病毒感染之治療
TWI698430B (zh) 2015-02-13 2020-07-11 南北兄弟藥業投資有限公司 三環化合物及其在藥物中的應用
KR102681304B1 (ko) 2015-03-31 2024-07-03 이난타 파마슈티칼스, 인코포레이티드 Fxr/tgr5 작용제로서의 담즙산 유도체 및 이의 이용 방법
PE20180690A1 (es) 2015-04-27 2018-04-23 Intercept Pharmaceuticals Inc Composiciones de acido obeticolico y metodos de uso
MA42819A (fr) 2015-09-16 2018-07-25 Gilead Sciences Inc Procédés pour le traitement d'infections virales à arenaviridae et coronaviridae
WO2017189651A1 (en) 2016-04-26 2017-11-02 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as fxr agonists and methods of use thereof
US10080741B2 (en) 2016-04-26 2018-09-25 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as FXR agonists and methods of use thereof
WO2017189663A1 (en) 2016-04-26 2017-11-02 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as fxr agonists and methods of use thereof
WO2017201150A1 (en) * 2016-05-18 2017-11-23 Enanta Pharmaceuticals, Inc. Isoxazole analogs as fxr agonists and methods of use thereof
US10149835B2 (en) 2016-05-18 2018-12-11 Elmore Patent Law Group, P.C. Isoxazole derivatives as FXR agonists and methods of use thereof
WO2017201152A1 (en) * 2016-05-18 2017-11-23 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as fxr agonists and methods of use thereof
ES2921432T3 (es) 2016-06-13 2022-08-25 Gilead Sciences Inc Derivados de azetidina como moduladores de FXR (NR1H4)
CA2968836A1 (en) 2016-06-13 2017-12-13 Gilead Sciences, Inc. Fxr (nr1h4) modulating compounds
ES2826748T3 (es) 2016-09-02 2021-05-19 Gilead Sciences Inc Derivados de 4,6-diamino-pirido[3,2-d]pirimidina como moduladores de receptores de tipo Toll
KR102268448B1 (ko) 2016-09-02 2021-06-22 길리애드 사이언시즈, 인코포레이티드 톨 유사 수용체 조정제 화합물
WO2018064373A1 (en) * 2016-09-28 2018-04-05 Eiger Biopharmaceuticals, Inc. Methods and pharmaceutical compositions for the treatment of non-alcoholic steatohepatitis
MX2019003790A (es) 2016-10-04 2019-09-26 Enanta Pharm Inc Analogos de isoxazol como agonistas de fxr y metodos de uso de los mismos.
KR20230010826A (ko) 2016-10-14 2023-01-19 프리시젼 바이오사이언시스 인코포레이티드 B형 간염 바이러스 게놈 내의 인식 서열에 대해 특이적인 조작된 메가뉴클레아제
WO2018081285A1 (en) 2016-10-26 2018-05-03 Enanta Pharmaceuticals, Inc. Urea-containing isoxazole derivatives as fxr agonists and methods of use thereof
CN108017636A (zh) * 2016-11-04 2018-05-11 合帕吉恩治疗公司 作为fxr调节剂的含氮杂环化合物
TWI820984B (zh) 2017-01-31 2023-11-01 美商基利科學股份有限公司 替諾福韋埃拉酚胺(tenofovir alafenamide)之晶型
AU2018235754B2 (en) 2017-03-14 2021-04-08 Gilead Sciences, Inc. Methods of treating feline coronavirus infections
EP4122464B1 (en) 2017-03-28 2024-05-15 Gilead Sciences, Inc. Therapeutic combinations for treating liver diseases
CN110944635A (zh) * 2017-03-30 2020-03-31 国家医疗保健研究所 用于减少附加体病毒的持久性和表达的方法和药物组合物
JOP20180040A1 (ar) 2017-04-20 2019-01-30 Gilead Sciences Inc مثبطات pd-1/pd-l1
CA3178212A1 (en) 2017-05-01 2018-11-08 Gilead Sciences, Inc. Crystalline forms of (s)-2-ethylbutyl 2-(((s)-(((2r,3s,4r,5r)-5-(4-aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(phenoxy) phosphoryl)amino)propanoate
TW201919648A (zh) 2017-07-11 2019-06-01 美商基利科學股份有限公司 用於治療病毒感染之含rna聚合酶抑制劑與環糊精的組合物
KR102114394B1 (ko) 2017-08-30 2020-05-22 경희대학교 산학협력단 벤조페논 유도체, 이의 제조방법 및 이를 포함하는 b형간염 치료용 약학적 조성물
US10689391B2 (en) 2017-12-12 2020-06-23 Enanta Pharmaceuticals, Inc. Isoxazole analogs as FXR agonists and methods of use thereof
AU2018392213B2 (en) 2017-12-20 2021-03-04 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3' cyclic dinucleotides with phosphonate bond activating the STING adaptor protein
CN111511754B (zh) 2017-12-20 2023-09-12 捷克共和国有机化学与生物化学研究所 活化sting转接蛋白的具有膦酸酯键的2’3’环状二核苷酸
CN110128432B (zh) 2018-02-02 2021-03-02 广东东阳光药业有限公司 含氮三环化合物及其在药物中的应用
KR102708681B1 (ko) 2018-02-13 2024-09-26 길리애드 사이언시즈, 인코포레이티드 Pd-1/pd-l1 억제제
US10829486B2 (en) 2018-02-14 2020-11-10 Enanta Pharmacueticals, Inc. Isoxazole derivatives as FXR agonists and methods of use thereof
WO2019165374A1 (en) 2018-02-26 2019-08-29 Gilead Sciences, Inc. Substituted pyrrolizine compounds as hbv replication inhibitors
US10870691B2 (en) 2018-04-05 2020-12-22 Gilead Sciences, Inc. Antibodies and fragments thereof that bind hepatitis B virus protein X
TW202005654A (zh) 2018-04-06 2020-02-01 捷克科學院有機化學與生物化學研究所 2,2,─環二核苷酸
TWI833744B (zh) 2018-04-06 2024-03-01 捷克科學院有機化學與生物化學研究所 3'3'-環二核苷酸
TWI818007B (zh) 2018-04-06 2023-10-11 捷克科學院有機化學與生物化學研究所 2'3'-環二核苷酸
US11142750B2 (en) 2018-04-12 2021-10-12 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome
CN112041311B (zh) 2018-04-19 2023-10-03 吉利德科学公司 Pd-1/pd-l1抑制剂
TW202014193A (zh) 2018-05-03 2020-04-16 捷克科學院有機化學與生物化學研究所 包含碳環核苷酸之2’3’-環二核苷酸
SI3820572T1 (sl) 2018-07-13 2023-12-29 Gilead Sciences, Inc. Inhibitorji pd-1/pd-l1
WO2020028097A1 (en) 2018-08-01 2020-02-06 Gilead Sciences, Inc. Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid
CA3117199C (en) 2018-10-24 2024-03-19 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
TWI721624B (zh) 2018-10-31 2021-03-11 美商基利科學股份有限公司 經取代之6-氮雜苯并咪唑化合物
ES2979163T3 (es) 2018-10-31 2024-09-24 Gilead Sciences Inc Compuestos de 6-azabenzimidazol sustituidos como inhibidores de HPK1
IL284591B2 (en) 2019-01-15 2025-04-01 Gilead Sciences Inc FXR (NR1H4) Modulating Compounds
CN118388474A (zh) 2019-02-19 2024-07-26 吉利德科学公司 Fxr激动剂的固体形式
CN113574063B (zh) 2019-03-07 2025-03-18 捷克共和国有机化学与生物化学研究所 3’3’-环二核苷酸及其前药
US11766447B2 (en) 2019-03-07 2023-09-26 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3′3′-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
KR102707808B1 (ko) 2019-03-07 2024-09-19 인스티튜트 오브 오가닉 케미스트리 앤드 바이오케미스트리 에이에스 씨알 브이.브이.아이. 2'3'-사이클릭 다이뉴클레오티드 및 이의 프로드럭
TW202104210A (zh) 2019-04-17 2021-02-01 美商基利科學股份有限公司 Hiv蛋白酶抑制劑
TW202212339A (zh) 2019-04-17 2022-04-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TW202210480A (zh) 2019-04-17 2022-03-16 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
US11555032B2 (en) 2019-05-13 2023-01-17 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as FXR agonists and methods of use thereof
TWI826690B (zh) 2019-05-23 2023-12-21 美商基利科學股份有限公司 經取代之烯吲哚酮化物及其用途
PE20220231A1 (es) 2019-06-25 2022-02-07 Gilead Sciences Inc Proteinas de fusion flt3l-fc y metodos de uso
CA3139750A1 (en) 2019-07-18 2021-01-21 Jacky Vonderscher Improved treatment using eyp001
WO2021011891A1 (en) 2019-07-18 2021-01-21 Gilead Sciences, Inc. Long-acting formulations of tenofovir alafenamide
CN114173784B (zh) * 2019-07-18 2023-12-01 埃尼奥制药公司 降低干扰素的副作用的方法
AU2020314081A1 (en) * 2019-07-18 2022-01-06 Enyo Pharma Synergistic effect of EYP001 and IFN for the treatment of HBV infection
EP4017476A1 (en) 2019-08-19 2022-06-29 Gilead Sciences, Inc. Pharmaceutical formulations of tenofovir alafenamide
KR20250040096A (ko) 2019-09-30 2025-03-21 길리애드 사이언시즈, 인코포레이티드 Hbv 백신 및 hbv를 치료하는 방법
WO2021108974A1 (en) * 2019-12-03 2021-06-10 Gannex Pharma Co., Ltd Compounds for modulating activity of fxr and uses thereof
EP4567109A2 (en) 2019-12-06 2025-06-11 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome
EP4081305B1 (en) 2019-12-24 2024-09-18 Carna Biosciences, Inc. Diacylglycerol kinase modulating compounds
WO2021144330A1 (en) * 2020-01-15 2021-07-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of fxr agonists for treating an infection by hepatitis d virus
TW202313067A (zh) 2020-01-27 2023-04-01 美商基利科學股份有限公司 治療sars cov-2感染之方法
EP4118085A2 (en) 2020-03-12 2023-01-18 Gilead Sciences, Inc. Methods of preparing 1'-cyano nucleosides
WO2021188695A1 (en) * 2020-03-18 2021-09-23 Metacrine, Inc. Formulations of a farnesoid x receptor agonist
EP4121437A1 (en) 2020-03-20 2023-01-25 Gilead Sciences, Inc. Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same
US11701372B2 (en) 2020-04-06 2023-07-18 Gilead Sciences, Inc. Inhalation formulations of 1'-cyano substituted carba-nucleoside analogs
KR20200049728A (ko) 2020-04-24 2020-05-08 경희대학교 산학협력단 벤조페논 유도체, 이의 제조방법 및 이를 포함하는 b형간염 치료용 약학적 조성물
US11975012B2 (en) 2020-05-29 2024-05-07 Gilead Sciences, Inc. Remdesivir treatment methods
JP2023531524A (ja) 2020-06-24 2023-07-24 ギリアード サイエンシーズ, インコーポレイテッド 1’-シアノヌクレオシド類似体及びその使用
CA3186054A1 (en) 2020-08-07 2022-02-10 Daniel H. BYUN Prodrugs of phosphonamide nucleotide analogues and their pharmaceutical use
EP4200301B1 (en) 2020-08-24 2025-02-26 Gilead Sciences, Inc. Phospholipid compounds and uses thereof
US11926645B2 (en) 2020-08-27 2024-03-12 Gilead Sciences, Inc. Compounds and methods for treatment of viral infections
WO2022076683A1 (en) * 2020-10-07 2022-04-14 Intercept Pharmaceuticals, Inc. Methods of treating coronaviral infection with obeticholic acid
TW202344257A (zh) 2020-10-16 2023-11-16 美商基利科學股份有限公司 磷脂化合物及其用途
TW202406932A (zh) 2020-10-22 2024-02-16 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
US20240100125A1 (en) 2021-01-14 2024-03-28 Enyo Pharma Synergistic effect of a fxr agonist and ifn for the treatment of hbv infection
KR20240009411A (ko) * 2021-04-16 2024-01-22 베이징 베스트 패스웨이 매니지먼트 컨설팅 센터 (리미티드 파트너쉽) Fxr 조절인자, 이의 제조 방법, 이의 약제학적 조성물 및 이의 용도
US20240269142A1 (en) 2021-05-13 2024-08-15 Gilead Sciences, Inc. COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS
WO2022251318A1 (en) 2021-05-26 2022-12-01 Gilead Sciences, Inc. Phospholipid formulations of 1'-cyano substituted carba-nucleoside analogs
WO2022271650A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
IL309378A (en) 2021-06-23 2024-02-01 Gilead Sciences Inc Diacylglyercol kinase modulating compounds
CN117355531A (zh) 2021-06-23 2024-01-05 吉利德科学公司 二酰基甘油激酶调节化合物
EP4359411A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
AU2022328698B2 (en) 2021-08-18 2025-02-20 Gilead Sciences, Inc. Phospholipid compounds and methods of making and using the same
JP2025014084A (ja) * 2021-12-07 2025-01-29 慶應義塾 ウイルス増殖抑制剤
IL315102A (en) 2022-03-02 2024-10-01 Gilead Sciences Inc COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS
KR20240154646A (ko) 2022-03-02 2024-10-25 길리애드 사이언시즈, 인코포레이티드 바이러스성 감염 치료를 위한 화합물 및 방법
CN118900839A (zh) 2022-03-03 2024-11-05 吉利德科学公司 抗病毒化合物及其制备和使用方法
AU2023227850A1 (en) 2022-03-03 2024-09-26 Gilead Sciences, Inc. Antiviral compounds and methods of making and using the same
CN119604286A (zh) 2022-06-06 2025-03-11 吉利德科学公司 用于治疗包括sars-cov-2的病毒感染的方法
WO2024006376A1 (en) 2022-06-29 2024-01-04 Gilead Sciences, Inc. Solid forms of a nucleoside analogue and uses thereof
US20240043466A1 (en) 2022-06-30 2024-02-08 Gilead Sciences, Inc. Solid forms of a nucleoside analogue and uses thereof
US20240309028A1 (en) 2023-02-16 2024-09-19 Gilead Sciences, Inc. Phospholipid compounds and methods of making and using the same
WO2025049493A1 (en) 2023-08-31 2025-03-06 Gilead Sciences, Inc. Antiviral compounds and methods of making and using the same
WO2025049699A1 (en) 2023-08-31 2025-03-06 Gilead Sciences, Inc. Antiviral compounds and methods of making and using the same
US20250099476A1 (en) 2023-09-06 2025-03-27 Gilead Sciences, Inc. Solid forms of a nucleoside analogue and uses thereof
WO2025072641A1 (en) 2023-09-28 2025-04-03 Gilead Sciences, Inc. Compounds and methods for treatment of viral infections
US12357577B1 (en) 2024-02-02 2025-07-15 Gilead Sciences, Inc. Pharmaceutical formulations and uses thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0692487A1 (en) * 1993-03-31 1996-01-17 Tokyo Tanabe Company Limited Cholestasis ameliorant
WO2006044391A1 (en) * 2004-10-14 2006-04-27 Intercept Pharmaceuticals Inc. A method of reducing drug-induced adverse side effects in a patient
WO2008002573A2 (en) * 2006-06-27 2008-01-03 Intercept Pharmaceuticals, Inc. Bile acid derivatives as fxr ligands for the prevention or treatment of fxr-mediated deseases or conditions
WO2010069604A1 (en) * 2008-12-19 2010-06-24 Royal College Of Surgeons In Ireland Treatment of diarrhoea
DE102010012226A1 (de) * 2010-03-19 2011-09-22 Acrovis Biostructures Gmbh Pharmazeutisches Kombinationspräparat

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6005086A (en) 1995-01-13 1999-12-21 The Salk Institute For Biological Studies Farnesoid activated receptor polypeptides, and nucleic acid encoding the same
ES2326850T3 (es) 1998-12-23 2009-10-20 Glaxo Group Limited Ensayos para ligandos de receptores nucleares.
WO2000040965A1 (en) 1999-01-07 2000-07-13 Tularik, Inc. Fxr receptor-mediated modulation of cholesterol metabolism
US20020132223A1 (en) 1999-03-26 2002-09-19 City Of Hope Methods for modulating activity of the FXR nuclear receptor
WO2000076523A1 (en) 1999-06-11 2000-12-21 Allergan Sales, Inc. Methods for modulating fxr receptor activity
JP2003508529A (ja) 1999-09-08 2003-03-04 グラクソ グループ リミテッド オキサゾールppar拮抗薬
IL157816A0 (en) 2001-03-12 2004-03-28 Roberto Pellicciari Steroids as agonists for fxr
EP1285914B1 (en) 2001-08-13 2007-12-19 PheneX Pharmaceuticals AG Nr1h4 nuclear receptor binding compounds
US20070010562A1 (en) 2001-08-13 2007-01-11 Ulrike Bauer Nr1h4 nuclear receptor binding compounds
WO2003060078A2 (en) 2001-12-21 2003-07-24 X-Ceptor Therapeutics, Inc. Heterocyclic modulators of nuclear receptors
US20050107475A1 (en) 2002-03-21 2005-05-19 Jones Stacey A. Methods of using farnesoid x receptor (frx) agonists
US6987121B2 (en) 2002-04-25 2006-01-17 Smithkline Beecham Corporation Compositions and methods for hepatoprotection and treatment of cholestasis
ITMI20021532A1 (it) 2002-07-12 2004-01-12 Roberto Pellicciari Composti chimici
AU2003290796A1 (en) 2002-11-14 2004-06-15 The Scripps Research Institute Non-steroidal fxr agonists
US20050143449A1 (en) 2002-11-15 2005-06-30 The Salk Institute For Biological Studies Non-steroidal farnesoid X receptor modulators and methods for the use thereof
US7319109B2 (en) 2002-11-22 2008-01-15 Smith Kline Beecham Corporation Farnesoid X receptor agonists
KR100545898B1 (ko) 2003-07-02 2006-01-25 동부아남반도체 주식회사 반도체 소자의 양자점 형성방법
US20070015796A1 (en) 2003-09-26 2007-01-18 Smithkline Beecham Corporation Compositions and methods for treatment of fibrosis
EP1568706A1 (en) 2004-02-26 2005-08-31 Intercept Pharmaceuticals, Inc. Novel steroid agonist for FXR
JP5094384B2 (ja) * 2004-03-12 2012-12-12 インターセプト ファーマシューティカルズ, インコーポレイテッド Fxrリガンドを使用する線維症の処置
JP2005281155A (ja) 2004-03-29 2005-10-13 Japan Health Science Foundation Fxr活性化を介したコレステロールホメオスタシス関連遺伝子転写活性調節剤
WO2005092328A1 (ja) 2004-03-29 2005-10-06 Japan Health Sciences Foundation Fxr活性化化合物
WO2005097097A1 (ja) 2004-04-02 2005-10-20 Japan Health Sciences Foundation Fxr活性化を介したコレステロールホメオスタシス関連遺伝子転写活性調節剤
US7902237B2 (en) 2004-08-10 2011-03-08 Exelixis, Inc. Heterocyclic compounds as pharmaceutical agents
WO2007052843A1 (ja) 2005-11-04 2007-05-10 Takeda Pharmaceutical Company Limited 複素環アミド化合物およびその用途
WO2007076260A2 (en) 2005-12-19 2007-07-05 Smithkline Beecham Corporation Farnesoid x receptor agonists
CN101374834B (zh) 2006-02-03 2011-12-14 伊莱利利公司 用于调节fxr的化合物和方法
JP5225984B2 (ja) 2006-05-24 2013-07-03 イーライ リリー アンド カンパニー Fxrを調節する化合物及び方法
BRPI0712262A2 (pt) 2006-05-24 2012-07-10 Lilly Co Eli agonistas de fxr
EP2038259A1 (en) 2006-06-29 2009-03-25 F.Hoffmann-La Roche Ag Benzimidazole derivatives, method for the production thereof, their use as fxr agonists and pharmaceutical preparations containing the same
US20080038435A1 (en) 2006-08-01 2008-02-14 Van Miller Precursor Formulation for Whippable Topping or Dessert Filling
EP1886685A1 (en) * 2006-08-11 2008-02-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods, uses and compositions for modulating replication of hcv through the farnesoid x receptor (fxr) activation or inhibition
EP1894924A1 (en) 2006-08-29 2008-03-05 Phenex Pharmaceuticals AG Heterocyclic FXR binding compounds
EP1894928A1 (en) 2006-08-29 2008-03-05 PheneX Pharmaceuticals AG Heterocyclic fxr binding compounds
CL2007003035A1 (es) 2006-10-24 2008-05-16 Smithkline Beechman Corp Compuestos derivados de isoxazol sustituidos, agonistas de receptores farnesoid x; procedimiento de preparacion; composicion farmaceutica que lo comprende; y uso del compuesto en el tratamiento de la obesidad, diabetes mellitus, fibrosis en organos,
JP5399262B2 (ja) 2006-12-08 2014-01-29 エグゼリクシス パテント カンパニー エルエルシー Lxrおよびfxrのモジュレーター
US9623021B2 (en) * 2007-01-22 2017-04-18 Gtx, Inc. Nuclear receptor binding agents
US20080300235A1 (en) 2007-06-01 2008-12-04 Wyeth FXR Agonists for Reducing LOX-1 Expression
CN101977505A (zh) * 2007-06-13 2011-02-16 葛兰素史密丝克莱恩有限责任公司 类法尼醇x受体激动剂
CN101877966A (zh) 2007-07-02 2010-11-03 葛兰素史密丝克莱恩有限责任公司 类法尼醇x受体激动剂
TW200906823A (en) 2007-07-16 2009-02-16 Lilly Co Eli Compounds and methods for modulating FXR
MX2010002341A (es) 2007-08-27 2010-03-22 Hoffmann La Roche Derivados de bencimidazol usados como agonistas del receptor x de farnesoide.
US8338628B2 (en) 2007-08-28 2012-12-25 City Of Hope Method of synthesizing alkylated bile acid derivatives
WO2009062874A2 (en) 2007-11-15 2009-05-22 F. Hoffmann-La Roche Ag Benzimidazole derivatives and their use as fxr agonists
US20090215748A1 (en) 2007-12-20 2009-08-27 Wyeth FXR agonists for treating vitamin D associated diseases
US7816540B2 (en) 2007-12-21 2010-10-19 Hoffmann-La Roche Inc. Carboxyl- or hydroxyl-substituted benzimidazole derivatives
EP2110374A1 (en) 2008-04-18 2009-10-21 Merck Sante Benzofurane, benzothiophene, benzothiazol derivatives as FXR modulators
EP2128158A1 (en) 2008-05-26 2009-12-02 Phenex Pharmaceuticals AG Heterocyclic cyclopropyl-substituted FXR binding compounds
EP2321282B1 (en) 2008-09-11 2013-03-27 F. Hoffmann-La Roche AG New benzimidazole derivatives
JP5450632B2 (ja) 2008-09-25 2014-03-26 エフ.ホフマン−ラ ロシュ アーゲー 3−アミノ−インダゾール又は3−アミノ−4,5,6,7−テトラヒドロインダゾール誘導体
EP2344459B1 (en) 2008-09-25 2013-12-25 F. Hoffmann-La Roche AG 2,3-substituted indazole or 4,5,6,7-tetrahydro-indazoles as fxr modulators against dyslipidemia and related diseases
ES2444791T3 (es) 2008-10-15 2014-02-26 F. Hoffmann-La Roche Ag Nuevos derivados de benzimidazol
EP2289883A1 (en) 2009-08-19 2011-03-02 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
US8309581B2 (en) 2009-09-29 2012-11-13 Hoffmann-La Roche Inc. Benzimidazole derivatives
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
WO2013037482A1 (en) 2011-09-15 2013-03-21 Phenex Pharmaceuticals Ag Farnesoid x receptor agonists for cancer treatment and prevention
US9930947B2 (en) 2015-09-19 2018-04-03 Hot Concepts, LLC Payment card enclosure system and methods of manufacturing and use

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0692487A1 (en) * 1993-03-31 1996-01-17 Tokyo Tanabe Company Limited Cholestasis ameliorant
WO2006044391A1 (en) * 2004-10-14 2006-04-27 Intercept Pharmaceuticals Inc. A method of reducing drug-induced adverse side effects in a patient
WO2008002573A2 (en) * 2006-06-27 2008-01-03 Intercept Pharmaceuticals, Inc. Bile acid derivatives as fxr ligands for the prevention or treatment of fxr-mediated deseases or conditions
WO2010069604A1 (en) * 2008-12-19 2010-06-24 Royal College Of Surgeons In Ireland Treatment of diarrhoea
DE102010012226A1 (de) * 2010-03-19 2011-09-22 Acrovis Biostructures Gmbh Pharmazeutisches Kombinationspräparat

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
A. MENCARELLI, B. RENGA, M. MIGLIORATI, S. CIPRIANI, E. DISTRUTTI, L. SANTUCCI, S. FIORUCCI: "The Bile Acid Sensor Farnesoid X Receptor Is a Modulator of Liver Immunity in a Rodent Model of Acute Hepatitis", THE JOURNAL OF IMMUNOLOGY, AMERICAN ASSOCIATION OF IMMUNOLOGISTS, vol. 183, no. 10, 15 November 2009 (2009-11-15), pages 6657 - 6666, XP055086353, ISSN: 00221767, DOI: 10.4049/jimmunol.0901347 *
RAMIERE CHRISTOPHE; SCHOLTES CAROLINE; DIAZ OLIVIER; ICARD VINCA; PERRIN-COCON LAURE; TRABAUD MARY-ANNE; LOTTEAU VINCENT; ANDRE PA: "Transactivation of the Hepatitis B Virus Core Promoter by the Nuclear Receptor FXR alpha", JOURNAL OF VIROLOGY., THE AMERICAN SOCIETY FOR MICROBIOLOGY., US, vol. 82, no. 21, 1 November 2008 (2008-11-01), US, pages 10832 - 10840, XP009173938, ISSN: 0022-538X, DOI: 10.1128/JVI.00883-08 *

Also Published As

Publication number Publication date
JP2018168179A (ja) 2018-11-01
AU2014320463A1 (en) 2016-04-07
HUE052856T2 (hu) 2021-05-28
JP6366721B2 (ja) 2018-08-01
RS61540B1 (sr) 2021-04-29
CN110404073A (zh) 2019-11-05
JP2016531144A (ja) 2016-10-06
EP3043865A1 (en) 2016-07-20
SMT202000669T1 (it) 2021-03-15
AU2014320463B2 (en) 2018-08-02
US20160220586A1 (en) 2016-08-04
KR20160127710A (ko) 2016-11-04
PL3043865T3 (pl) 2021-07-05
US9895380B2 (en) 2018-02-20
CN105764569B (zh) 2019-09-13
DK3043865T3 (da) 2021-02-01
IL244431B (en) 2019-03-31
BR112016005507B1 (pt) 2023-02-07
ES2846183T3 (es) 2021-07-28
AU2018236856B2 (en) 2018-12-20
EA201690556A1 (ru) 2016-07-29
CN105764569A (zh) 2016-07-13
JP6402277B1 (ja) 2018-10-10
HK1220935A1 (en) 2017-05-19
CA2923090C (en) 2018-08-21
LT3043865T (lt) 2021-04-26
PT3043865T (pt) 2021-01-14
CA2923090A1 (en) 2015-03-19
MX2016003216A (es) 2016-09-13
MY186752A (en) 2021-08-18
CN110404073B (zh) 2022-08-16
US20180169115A1 (en) 2018-06-21
EP3043865B1 (en) 2020-11-04
CY1123962T1 (el) 2022-03-24
BR112016005507A2 (enrdf_load_stackoverflow) 2017-08-01
IL244431A0 (en) 2016-04-21
WO2015036442A1 (en) 2015-03-19
PH12016500431A1 (en) 2016-05-16
AU2018236856A1 (en) 2018-10-18
US10071108B2 (en) 2018-09-11
KR101949251B1 (ko) 2019-02-18
PH12016500431B1 (en) 2016-05-16
MX377523B (es) 2025-03-10
HRP20201953T1 (hr) 2021-04-30
EP3711762A1 (en) 2020-09-23
SI3043865T1 (sl) 2021-04-30

Similar Documents

Publication Publication Date Title
JP6402277B1 (ja) B型肝炎ウイルス感染症を処置するための方法及び医薬組成物
US20210322404A1 (en) Fgfr regulation for the treatment of viral infections
ZA200703600B (en) Medicaments for the treatment or prevention of fibrotic diseases
JP6247004B2 (ja) 帯状疱疹関連通の急性期疼痛の予防又は治療剤
EP4090327B1 (en) Use of fxr agonists for treating an infection by hepatitis d virus
HK40037859A (en) A farnesoid x receptor agonsits foruse and pharmaceutical compositions for the treatment of chronic hepatitis b virus infection
HK1220935B (en) Method and pharmaceutical compositions for the treatment of hepatitis b virus infection
Kim et al. Blockade of urotensin II receptor prevents vascular dysfunction
US20250228850A1 (en) Combination of a cxcr7 antagonist with an s1p1 receptor modulator
US20190070153A1 (en) Compositions and methods for treating pulmonary diseases
WO2005070432A1 (en) Use of pdgf-r tk inhibitors for the treatment of myocarditis and its complications
CN102274232A (zh) 腺苷受体a1拮抗剂在制备药物中的应用